Therapeutics News and Research

RSS

Study challenges assumptions about testosterone’s role in brain cancer

Scientists have long suspected that androgens, male sex hormones like testosterone, may help tumors grow because the hormones can suppress immune responses to some cancers.

8 May 2026

The BHARAT study: India’s first large-scale search for aging biomarkers

A new research paper was published in Volume 18 of Aging-US on April 24, 2026, titled "The BHARAT study: a multi-modal, multi-omics investigation of aging signatures in the Indian population."

8 May 2026

JAYseq test delivers rapid genomic profiling for multiple myeloma patients

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a clinical whole-genome sequencing (WGS) test specifically for multiple myeloma.

7 May 2026

Targeted RAS inhibitor shows promise against pancreatic cancer mutations

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

7 May 2026

New CRISPR system selectively destroys cancer cells

Among the challenges in treating disease, including cancer, is wiping out malignancies, infection, contaminants or other pathologies, without destroying healthy tissue.

6 May 2026

New immunotherapy strategy overcomes resistance in colorectal cancer treatment

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.

6 May 2026

4basebio announces lease of an innovation hub and manufacturing facility in Cambridge, UK

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines, genome editing, or DNA vaccines.

From 4basebio PLC 6 May 2026

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Study links antimicrobial peptides to amyloid disease and neurodegeneration

For decades, antimicrobial peptides (AMPs) and amyloid-forming peptides were studied in largely separate contexts.

5 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

Researchers leverage tamoxifen's active metabolite to improve breast cancer prevention

Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment of breast cancer.

4 May 2026

Extracellular vesicles from T cells enhance tumor immune response

Activated immune cells secrete tiny capsules bearing DNA that can enter other immune and tumor cells to stimulate the body's defense systems, according to a study led by investigators at Weill Cornell Medicine.

30 Apr 2026

New research shows weight loss is possible without GLP-1

Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.

30 Apr 2026

New imaging agent shows promise for non-invasive endometriosis diagnosis

The Nuffield Department of Women's & Reproductive Health at the University of Oxford, together with Serac Healthcare Limited announces the publication of Phase 2 data in The Lancet Obstetrics and Gynaecology.

29 Apr 2026

Researchers use light-activated nanozymes to treat aggressive brain tumors

Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack cancer cells directly in the brain during tumor surgery.

29 Apr 2026

Multiple myeloma mortality rates decline with advances in targeted therapies

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023."

29 Apr 2026

New genetic risk test estimates inherited risk for cardiovascular conditions

Researchers at Mass General Brigham Heart and Vascular Institute and collaborators have developed and validated a new genetic risk test that can estimate a person's inherited risk for eight common cardiovascular conditions, offering a more comprehensive approach to prevention.

29 Apr 2026